Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 560.00
Bid: 550.00
Ask: 566.00
Change: 10.00 (1.82%)
Spread: 16.00 (2.909%)
Open: 568.00
High: 568.00
Low: 550.00
Prev. Close: 550.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

2 Sep 2020 07:00

RNS Number : 7412X
Gooch & Housego PLC
02 September 2020
 

For immediate release

2 September 2020

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Trading Update

 

"Trading in line with expectations"

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, provides an update for the 10 months ended 31 July 2020. Overall, trading remains in line with management's expectations for the full year ending 30 September 2020.

Trading

The Group's manufacturing locations in the UK, USA and China are now fully open, thanks to measures that were quickly and efficiently put in place by our site teams, minimising the disruption of the COVID-19 pandemic for our customers whilst keeping our employees safe. Most recently, our Torquay site in the UK has returned to full capacity.

Trading levels in June and July reflected the recovery in the Company's manufacturing capacity and some of our larger customers' manufacturing sites reopening.

Orders for fibre optics, hi- reliability fibre couplers for undersea cables and our A&D and life science capabilities remain robust. There continues to be improved demand for medical diagnostics, in particular for ventilator systems. As previously communicated, industrial laser demand remains at below "normalised" levels, although the semiconductor subsector has demonstrated sustained improvement.

The previously announced cost control measures have been implemented and will support the Group's profitability in H2 FY '20 and beyond.

Priorities in the COVID-19 emergency

Our primary concern during the emergency is the health and safety of our staff, customers and suppliers. Extensive measures have been put in place at all of our sites to ensure we rigorously meet social distancing and cleanliness requirements and all other relevant guidelines and regulations.

Financial strength

The Company remains in a good financial position with a strong balance sheet and liquidity levels that have continued to improve during the period. Total headroom increased to £28.1 million; this included a $10 million extension to the Group's revolving credit facility taking the total to $50 million, as announced in April 2020.

Outlook

There remains significant global economic uncertainty due to the COVID-19 emergency in the short term. That said, our telecommunications, A&D and life sciences businesses have held up well during the period, though the timing and pace of the industrial laser market recovery remains difficult to predict.

Improved industrial laser demand will be driven by technical innovation such as 5G and new laser based manufacturing techniques. There remains substantial long term growth potential for our photonic technologies and system capabilities in all of our target sectors.

The streamlining of our manufacturing sites is on schedule and will deliver the profit improvements previously announced.

 

Mark Webster, Chief Executive Officer of Gooch and Housego, commented:

"We are proud of the way that our staff and management have responded to the COVID-19 emergency. All of our sites in the UK, USA and China are now open and fully compliant with all relevant health and safety requirements. This has been achieved, quickly, efficiently and most importantly, safely.

"While there remains considerable short term economic uncertainty our order book remains robust, the Company's balance sheet has strengthened during the period and we have continued to invest in our high priority R&D targets.

"The COVID-19 emergency has validated G&H's long term strategy of diversification and moving up the value chain. We will continue to pursue this policy through internal investment and where appropriate, acquisitions."

 

 

 

 

For further information contact: -

 

Mark Webster/Chris Jewell

Gooch & Housego PLC

01460 256440

Mark Court/ Charlotte Slater

Buchanan

020 7466 5000

Chris Baird/Patrick Robb/

David Anderson

Investec Bank plc

020 7597 5970

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSSDESFESSEFU
Date   Source Headline
24th Jun 20087:00 amRNSChange of NOMAD & Broker
17th Jun 20087:00 amRNSInterim Results
27th May 20087:00 amRNSIFRS
13th May 20086:00 amRNSNotice of Results
9th Apr 20087:00 amRNSTrading Update
28th Mar 20089:59 amRNSAnnual Report and Accounts
12th Mar 20084:37 pmRNSAdditional Listing
13th Feb 200811:00 amRNSAGM Statement
5th Feb 20087:01 amRNSVendor Appreciation Award
22nd Jan 20087:01 amRNSGlobal Integration
7th Jan 20088:53 amRNSAdditional Listing
7th Jan 20087:01 amRNSSIFAM Order
4th Jan 200812:32 pmRNSDirector Shareholding
21st Dec 20074:46 pmRNSHolding(s) in Company
21st Dec 20074:35 pmRNSAdditional Listing
7th Dec 20073:00 pmRNSLong Term Incentive Plan
3rd Dec 200712:20 pmRNSAdditional Listing
30th Nov 20073:44 pmRNSHolding(s) in Company
27th Nov 20077:00 amRNSAppointment
27th Nov 20077:00 amRNSPreliminary Results
15th Nov 20077:01 amRNSAppointment
29th Oct 20077:01 amRNSNotice of Results
4th Oct 20077:01 amRNSFull Year Trading Update
23rd Aug 20078:26 amRNSAdditional Listing
22nd Aug 20075:38 pmRNSDirector Shareholdings
17th Aug 20076:23 pmRNSAIM Rule 26
16th Aug 20072:12 pmRNSAdditional Listing
14th Aug 200712:36 pmRNSLTIP Awards
10th Aug 20075:18 pmRNSDirector Shareholdings
17th Jul 20074:16 pmRNSDirector of Sales Appointment
5th Jun 20077:02 amRNSInterim Results
31st May 20079:55 amRNSTotal Voting Rights
10th May 20079:58 amRNSHolding(s) in Company
9th May 20077:01 amRNSNotice of Results
8th May 20071:53 pmRNSAdditional Listing
8th May 20077:02 amRNSAcquisition
11th Apr 20077:01 amRNSTrading Update
8th Mar 20075:54 pmRNSHolding(s) in Company
14th Feb 20077:01 amRNSAGM Statement
8th Feb 20073:41 pmRNSHolding(s) in Company
1st Feb 200712:43 pmRNSTotal Voting Rights
1st Feb 200712:42 pmRNSHolding(s) in Company
9th Jan 200710:26 amRNSAdditional Listing
20th Dec 200611:54 amRNSTotal Voting Rights
30th Nov 200610:07 amRNSNotice of Dividend
29th Nov 200611:18 amRNSPreliminary Results-Amendment
29th Nov 20067:02 amRNSAppointment of Director
29th Nov 20067:02 amRNSPreliminary Results
2nd Nov 20067:01 amRNSNotice of Results
4th Oct 20067:00 amRNSFull Year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.